MAZE vs TMO vs BIO vs CRL

For growth investors, Thermo Fisher Scientific Inc.

(TMO) is the stronger pick with 3. 9% revenue growth year-over-year, versus -100. 0% for Maze Therapeutics, Inc. (MAZE). Bio-Rad Laboratories, Inc. (BIO) offers the better valuation at 10. 5x trailing P/E (32. 3x forward), making it the more compelling value choice. Analysts rate Maze Therapeutics, Inc. (MAZE) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bio-Rad Laboratories, Inc.

(BIO) is the cheapest at 10. 5x versus Thermo Fisher Scientific Inc. at 26. 8x. On forward P/E, Charles River Laboratories International, Inc. is actually cheaper at 17. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Maze Therapeutics, Inc.

(MAZE) delivered a total return of +51. 0%, compared to -51. 4% for Bio-Rad Laboratories, Inc. (BIO). Over 10 years, the gap is even starker: TMO returned +223. 2% versus MAZE's +51. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bio-Rad Laboratories, Inc.

(BIO) is the lower-risk stock at 0. 75β versus Charles River Laboratories International, Inc. 's 1. 42β — meaning CRL is approximately 89% more volatile than BIO relative to the S&P 500. On balance sheet safety, Maze Therapeutics, Inc. (MAZE) carries a lower debt/equity ratio of 7% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Thermo Fisher Scientific Inc.

(TMO) is pulling ahead at 3. 9% versus -100. 0% for Maze Therapeutics, Inc. (MAZE). On earnings-per-share growth, the picture is similar: Bio-Rad Laboratories, Inc. grew EPS 142. 6% year-over-year, compared to -40. 2% for Maze Therapeutics, Inc.. Over a 3-year CAGR, CRL leads at 0. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bio-Rad Laboratories, Inc.

(BIO) is the more profitable company, earning 29. 4% net margin versus -612. 7% for Maze Therapeutics, Inc. — meaning it keeps 29. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMO leads at 18. 2% versus -670. 3% for MAZE. At the gross margin level — before operating expenses — MAZE leads at 92. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Charles River Laboratories International, Inc.

(CRL) trades at 17. 0x forward P/E versus 32. 3x for Bio-Rad Laboratories, Inc. — 15. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MAZE: 162. 6% to $63. 25.

In this comparison, TMO (0.

4% yield) pays a dividend. MAZE, BIO, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Bio-Rad Laboratories, Inc.

(BIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 75), +101. 9% 10Y return). Both have compounded well over 10 years (BIO: +101. 9%, CRL: +123. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MAZE is a small-cap quality compounder stock; TMO is a mid-cap quality compounder stock; BIO is a small-cap deep-value stock; CRL is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.